Coagulation factor therapy for hemophilia: relation to hepatitis B and to liver function

Area of Science:

• Hematology
• Hepatology
• Transfusion Medicine

Background:

• Hemophilia management has improved with concentrated coagulation factors.
• The long-term effects of repeated blood product infusions on liver health in hemophilia patients remain unclear.
• Hepatic dysfunction is a common concern in hemophilia management.

Purpose of the Study:

• To investigate the relationship between liver function and the frequency and type of coagulation factor therapy in hemophilia patients.
• To assess the impact of concentrated coagulation factor infusions on liver health.
• To identify potential risk factors for hepatic dysfunction in hemophilia.

Main Methods:

• A study was conducted on 36 hemophilia patients.
• Liver function was assessed by measuring serum glutamic oxaloacetic transaminase (SGOT) levels.
• Patients' antibody status to hepatitis B surface antigen was determined.
• Therapy details, including factor type and infusion frequency, were analyzed.

Main Results:

• 75% of patients had hepatitis B surface antigen antibodies, and 44% had elevated SGOT levels.
• Infusions of concentrated coagulation factors more than once annually correlated significantly with hepatitis B antibodies and high SGOT.
• Patients receiving factor concentrates from large donor pools showed higher rates of hepatitis B antibodies but not elevated SGOT compared to those treated with cryoprecipitate, plasma, or whole blood.

Conclusions:

• The frequency of coagulation factor treatment appears to be a more significant factor in hepatic dysfunction among hemophilia patients than the type of treatment.
• Hepatitis B exposure, indicated by antibodies, is associated with frequent concentrated factor use.
• Further research is needed to fully elucidate the mechanisms linking coagulation factor therapy and liver health in hemophilia.